Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.

[1]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[2]  B. Monk,et al.  Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Tonini,et al.  Ovarian cancer standard of care: are there real alternatives? , 2015, Chinese journal of cancer.

[4]  Swati Suryawanshi,et al.  Plasma MicroRNAs as Novel Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer , 2013, Clinical Cancer Research.

[5]  E. Diamandis,et al.  Revisiting the Complexity of the Ovarian Cancer Microenvironment—Clinical Implications for Treatment Strategies , 2012, Molecular Cancer Research.

[6]  C. Helm,et al.  Ports and complications for intraperitoneal chemotherapy delivery , 2012, BJOG : an international journal of obstetrics and gynaecology.

[7]  C. Rancourt,et al.  Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients , 2011, BMC Cancer.

[8]  S. Beriwal,et al.  Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. , 2010, Gynecologic oncology.

[9]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[10]  J. Kelley,et al.  A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer , 2010, Cancer Immunology, Immunotherapy.

[11]  D. Levine,et al.  Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer. , 2008, Gynecologic oncology.

[12]  C. June,et al.  Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma , 2007, Journal of Translational Medicine.

[13]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[14]  R. Burger,et al.  Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2006, Gynecologic oncology.

[15]  B. Robinson,et al.  Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.

[16]  J. H. Price,et al.  Morphological effects of chemotherapy on ovarian carcinoma. , 2002, Journal of clinical pathology.

[17]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[19]  M Markman,et al.  Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[21]  P. Allavena,et al.  Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells. , 1990, Cancer research.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.